{
    "id": "36394241-a534-5f29-e063-6394a90abc8b",
    "indications": {
        "text": "valacyclovir hydrochloride nucleoside analogue dna polymerase inhibitor indicated : adult patients ( 1.1 ) cold sores ( herpes labialis ) genital herpes treatment immunocompetent patients ( initial recurrent episode ) suppression immunocompetent hiv-infected patients reduction transmission herpes zoster pediatric patients ( 1.2 ) cold sores ( herpes labialis ) chickenpox limitations ( 1.3 ) efficacy safety valacyclovir tablets , usp established immunocompromised patients suppression genital herpes hiv-infected patients .",
        "doid_entities": [
            {
                "text": "cold (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "genital herpes (DOID:8704)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8704"
            },
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "chickenpox (DOID:8659)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8659"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "valacyclovir tablets may given without regard meals . valacyclovir oral suspension ( 25 mg/ml 50 mg/ml ) may prepared extemporaneously 500 mg valacyclovir tablets pediatric patients solid form appropriate [ ( 2.3 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "valacyclovir tablets usp , 1 gram blue , film-coated , capsule shaped tablets partial scorebar sides containing f one side 8 3 otherside . ndc 68071-1548-3 bottles 30 store 20 25 oc ( 68 77 ) . [ usp controlled room temperature . ] dispense well-closed container defined usp .",
    "adverseReactions": "valacyclovir tablets contraindicated patients demonstrated clinically significant hypersensitivity reaction ( e.g . , anaphylaxis ) valacyclovir , acyclovir , component formulation [ ( 6.3 ) ] .",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9919"
        }
    ],
    "organization": "NuCare Pharmacuticals,Inc.",
    "name": "Valacyclovir Hydrochloride",
    "effectiveTime": "20250528",
    "indications_original": "Valacyclovir hydrochloride\u00a0is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients (1.1) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets, USP have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.",
    "contraindications_original": "Valacyclovir tablets may be given without regard to meals.    \n                     \n                        Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate \n         \n   \n    [see \n          \n    \n     Dosage and Administration (2.3)]\n         \n   \n    .",
    "warningsAndPrecautions_original": "Valacyclovir Tablets USP, 1 gram  are blue, film-coated, capsule shaped tablets with a partial scorebar on both sides containing F on one side and 8 and 3 on the otherside.\n \n                  \n                  \n                  \n                  \n                  NDC 68071-1548-3 Bottles of 30\n                  \n                  \n                  \n                     \n                     \n                     \n                     Store at 20 \n  o to 25 \n  oC (68 \n  o to 77 \n  oF). [See USP Controlled Room Temperature.]\n  \n                     \n                     \n                     \nDispense in a well-closed container as defined in the USP.",
    "adverseReactions_original": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation \n       \n \n  [see \n        \n  \n   Adverse Reactions (6.3)]\n       \n \n  .",
    "drug": [
        {
            "name": "Valacyclovir Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9919"
        }
    ]
}